- Company
- Who would manufacture Moderna vaccine in South Korea?
- by Kim, Jin-Gu Dec 31, 2020 06:20am
- President Moon Jae-in and Moderna CEO Stephane Bancel reportedly had a conference call over supplying COVID-19 vaccines for 20 million people in South Korea. Now the question is who would sign the consignment production contract for the vaccine in South Korea. The pharmaceutical industry is mentioning four names of potential candidates, incl
- Company
- Pradaxa and Xarelto to face generic market opening up soon
- by Kim, Jin-Gu Dec 30, 2020 06:03am
- Six South Korean pharmaceutical companies that successfully evaded Pradaxa (dabigatran) and Xarelto’s (rivaroxaban) patents would release generics in advance in July next year. The industry predicts the non-Vitamin K antagonist oral anticoagulants (NOAC) market currently led by the originals would take a sharp turn soon. Moreover, a generic
- Company
- Samsung Bio & Hanmi will participate at JPM 2021
- by Kim, Jin-Gu Dec 30, 2020 06:02am
- 20 domestic pharmaceutical bio companies announced their participation in the JPMorgan Healthcare Conference, which will be held early next year. Among them, Samsung Biologics was the only one to be assigned a main session presentation. Celltrion, who attended every time, declared absence after 10 years. The JPMorgan Healthcare Conferen
- Company
- Successful year for Korean new drug, biosimilar and test kit
- by An, Kyung-Jin Dec 29, 2020 06:09am
- The year 2020 was a fruitful year for the South Korean companies and their R&D outcomes showcased in the global market. Yuhan Corporation licensed out its novel lung cancer treatment ‘lazertinib’ to Janssen for 100 billion won. SK Biopharmaceutical put the gears in motion for its anti-epileptic drug Xcopri sales in the U.S. market. The
- Company
- High import drug dependency, Korean drug ratio keeps falling
- by Chon, Seung-Hyun Dec 29, 2020 06:08am
- The dependency on imported pharmaceutical products in the South Korean market seems to be getting higher. The volume of the country’s locally manufactured complete product and active pharmaceutical ingredient (API) has fallen for two consecutive years. The self-sufficiency in API has even halved in just two years. According to the ‘Food an
- Company
- Technology exports are active despite COVID-19 outbreak
- by An, Kyung-Jin Dec 28, 2020 06:14am
- The world is struggling with the surprise attack of COVID-19, but domestic pharmaceutical and bio companies' new drug technology export performance is very active. SK Biopharm received the most down payment for the second consecutive year as it transferred the copyright to the Japanese region for a new epilepsy drug developed with its own tec
- Company
- Hanmi and SK win the final round of Xarelto patent dispute
- by Kim, Jin-Gu Dec 28, 2020 06:13am
- South Korean pharmaceutical companies won the patent dispute on Bayer’s non-Vitamin K antagonist oral anticoagulants (NOAC) Xarelto (rivaroxaban). As a result, Hanmi Pharmaceutical and SK Chemicals have overcome the last obstacle to prepare an early launch of rivaroxaban generic in next October. On Dec. 24, the Supreme Court ruled in
- Company
- Multinational companies enjoy winter holidays up to 17 days
- by Eo, Yun-Ho Dec 24, 2020 06:10am
- This year, a number of multinational pharmaceutical companies' executives and staff members are entering long-term winter holidays. As a result of Dailypharm's survey of the year-end holidays of 20 major multinational companies on the 23rd, it was confirmed that more than 10 companies designated winter holidays for more than 10 days. In pa
- Company
- “Need to set up cold chain for COVID-19 vaccine ASAP”
- by Dec 24, 2020 06:09am
- “Pfizer and Moderna both use mRNA type of COVID-19 vaccines and it is a highly unstable substance that requires exceptional level of cold chain management. Especially, the response plan on how to react on an emergency, for instance malfunctioning storage tool or power outage, is the most important part.” A Sungkyunkwan University Col
- Company
- Domestic companies won the first trial of 12 patents
- by Kim, Jin-Gu Dec 23, 2020 06:09am
- This year, domestic pharmaceutical companies have challenged 12 new patents. In 4 out of 12 patent disputes, generic companies have won all of them, and the remaining 8 cases have yet to be tried. According to the pharmaceutical industry on the 21st, a total of 12 patent disputes pending from January this year to this day. Daewoong and Cho
